Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Rotavirus Infections | 4 | 2019 | 355 | 1.79 | Why? |
| Gastroenteritis | 3 | 2019 | 489 | 1.20 | Why? |
| Rotavirus | 2 | 2019 | 329 | 1.15 | Why? |
| Rotavirus Vaccines | 3 | 2019 | 203 | 0.91 | Why? |
| Poliovirus Vaccine, Oral | 2 | 2017 | 95 | 0.76 | Why? |
| Blood Group Antigens | 1 | 2019 | 202 | 0.66 | Why? |
| Poliovirus | 2 | 2017 | 109 | 0.66 | Why? |
| Caliciviridae Infections | 1 | 2019 | 229 | 0.62 | Why? |
| Feces | 4 | 2019 | 4235 | 0.62 | Why? |
| Virus Cultivation | 1 | 2017 | 579 | 0.51 | Why? |
| Genotype | 2 | 2019 | 4697 | 0.40 | Why? |
| Diarrhea | 2 | 2019 | 2743 | 0.39 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2017 | 1439 | 0.37 | Why? |
| Disease Susceptibility | 1 | 2019 | 4002 | 0.31 | Why? |
| India | 16 | 2021 | 11875 | 0.30 | Why? |
| Real-Time Polymerase Chain Reaction | 6 | 2020 | 11367 | 0.23 | Why? |
| Virus Shedding | 2 | 2017 | 5834 | 0.22 | Why? |
| Eligibility Determination | 1 | 2020 | 255 | 0.17 | Why? |
| Sri Lanka | 1 | 2018 | 241 | 0.17 | Why? |
| Intussusception | 1 | 2018 | 102 | 0.16 | Why? |
| Poliovirus Vaccine, Inactivated | 1 | 2017 | 72 | 0.16 | Why? |
| Asia, Southeastern | 1 | 2018 | 390 | 0.16 | Why? |
| Infant | 8 | 2020 | 30274 | 0.15 | Why? |
| Enterovirus Infections | 1 | 2019 | 404 | 0.13 | Why? |
| Nepal | 1 | 2018 | 1004 | 0.13 | Why? |
| Poliomyelitis | 1 | 2017 | 263 | 0.12 | Why? |
| Sentinel Surveillance | 1 | 2020 | 1093 | 0.12 | Why? |
| Hospitalization | 2 | 2019 | 54280 | 0.10 | Why? |
| Zinc | 1 | 2017 | 817 | 0.10 | Why? |
| Safety Management | 1 | 2018 | 1093 | 0.10 | Why? |
| Probiotics | 1 | 2017 | 694 | 0.10 | Why? |
| Child, Preschool | 5 | 2020 | 36283 | 0.09 | Why? |
| Gene Expression | 1 | 2019 | 3332 | 0.09 | Why? |
| Residence Characteristics | 1 | 2019 | 1927 | 0.09 | Why? |
| Clinical Laboratory Techniques | 4 | 2020 | 23402 | 0.08 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 7868 | 0.08 | Why? |
| Immunization Programs | 1 | 2019 | 2006 | 0.08 | Why? |
| Immunoglobulin A | 1 | 2017 | 3567 | 0.07 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Vaccination | 3 | 2019 | 19050 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.07 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.06 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.06 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.06 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.05 | Why? |
| Seroepidemiologic Studies | 3 | 2021 | 10017 | 0.05 | Why? |
| Antigens, Viral | 1 | 2018 | 6298 | 0.05 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.05 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.05 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2020 | 13720 | 0.05 | Why? |
| Humans | 18 | 2021 | 930598 | 0.05 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.05 | Why? |
| Specimen Handling | 3 | 2020 | 6190 | 0.04 | Why? |
| Lactobacillus rhamnosus | 1 | 2017 | 23 | 0.04 | Why? |
| Male | 10 | 2021 | 367725 | 0.04 | Why? |
| Microscopy, Electron, Transmission | 1 | 2020 | 605 | 0.04 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.04 | Why? |
| Female | 10 | 2021 | 380317 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Quality Control | 1 | 2020 | 628 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.04 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2017 | 593 | 0.04 | Why? |
| Genes, Viral | 1 | 2020 | 1428 | 0.04 | Why? |
| Placebos | 1 | 2017 | 629 | 0.03 | Why? |
| Sequence Alignment | 1 | 2020 | 2109 | 0.03 | Why? |
| Immunity, Mucosal | 1 | 2017 | 426 | 0.03 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.03 | Why? |
| Vaccines, Attenuated | 1 | 2017 | 952 | 0.03 | Why? |
| Phylogeny | 2 | 2020 | 13341 | 0.03 | Why? |
| Intestines | 1 | 2017 | 817 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Immunization Schedule | 1 | 2017 | 1305 | 0.02 | Why? |
| Immunization, Secondary | 1 | 2017 | 1649 | 0.02 | Why? |
| Cities | 1 | 2021 | 4937 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2020 | 2643 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3633 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Iran | 1 | 2020 | 5467 | 0.02 | Why? |
| Pandemics | 8 | 2020 | 389249 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2020 | 2844 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.02 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.02 | Why? |
| Immunoassay | 1 | 2021 | 4485 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.02 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Vero Cells | 1 | 2020 | 14117 | 0.02 | Why? |
| Adult | 4 | 2021 | 244371 | 0.01 | Why? |
| Middle Aged | 4 | 2021 | 270681 | 0.01 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.01 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.01 | Why? |
| Population Surveillance | 1 | 2018 | 4967 | 0.01 | Why? |
| Travel | 1 | 2020 | 7220 | 0.01 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.01 | Why? |
| Child | 2 | 2020 | 70012 | 0.01 | Why? |
| Treatment Outcome | 2 | 2017 | 51732 | 0.01 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.01 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.01 | Why? |
| Italy | 1 | 2020 | 38444 | 0.01 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.01 | Why? |
| Aged | 2 | 2020 | 215776 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.01 | Why? |
| Animals | 1 | 2020 | 78931 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2017 | 25288 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.01 | Why? |
Giri's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(115)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(133)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_